Finance entity
All 3 tracked stories fall under one category: markets. AbbVie is the most frequent co-covered peer, appearing in 1 of the 3 tracked stories. Each story carries 2 original sources on average, compared with 2.7 for the broader beat in this window.
Last mentioned: 5d ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 3 tracked stories fall under one category: markets. AbbVie is the most frequent co-covered peer, appearing in 1 of the 3 tracked stories. Each story carries 2 original sources on average, compared with 2.7 for the broader beat in this window. That works out to roughly 0.1 stories per week across a 192-day span. Their average consequence score of 5.7 runs below the beat's 6.2 for that window. We currently track 3 Finance stories that mention RBC Capital, published between February 27, 2026 and September 6, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 3901 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering RBC Capital. Shared-story counts are live from our verified record — not editorial picks.
TD Cowen Conference
AbbVie management is scheduled to speak at the TD Cowen Health Care Conference.
DOJ Legal Support
The Department of Justice backs AbbVie in its challenge against a Colorado drug discount program law.
RBC Coverage Launch
RBC Capital Markets initiates coverage with an Outperform rating, citing durable growth.
Humira Exclusivity Ends
The first biosimilar for Humira enters the U.S. market, marking the start of the 'Humira cliff'.
UiPath shares jumped 46.3% in August as enterprise software rebounded from AI-disruption fears and RBC Capital lifted price targets. The move preceded a fiscal Q2 report that fell short of elevated hopes, showing how much of the gain was sector sentiment rather than stock-specific news.
RBC Capital maintains a positive outlook on Eli Lilly, identifying Retatrutide as a primary growth engine for the pharmaceutical giant. Despite recent mixed clinical trial results, analysts believe the drug's triple-agonist mechanism offers a significant competitive edge in the global obesity market.
RBC Capital has initiated coverage of AbbVie with an 'Outperform' rating, signaling confidence in the company's ability to navigate the post-Humira landscape. Analysts believe the market has over-discounted the growth potential of AbbVie's next-generation immunology drugs and its durable aesthetics portfolio.
RBC Capital is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
